Titan Biotech reported a 50.20% year-on-year increase in net profit to ₹2,744.72 lakh for the financial year ended March 31, 2026. Revenue from operations for the year rose to ₹20,619.03 lakh from ₹15,645.08 lakh in the previous year, while total income increased to ₹21,160.05 lakh. The Board of Directors has recommended a dividend of ₹0.50 per equity share, subject to approval by shareholders at the ensuing Annual General Meeting.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹655.57 lakh, compared to ₹376.61 lakh in the corresponding period of the previous year. Revenue from operations for the quarter stood at ₹4,883.35 lakh, against ₹3,520 lakh in the year-ago period. Q4 EBITDA came in at 97M rupees, compared to 46M rupees in the same quarter of the previous year, with the EBITDA margin expanding to 19.89% from 12.99% year-on-year. The statutory auditors, A N S K & Associates, issued an unmodified opinion on the standalone and consolidated financial results.

Financial Performance

The company's total expenses for FY26 amounted to ₹17,342.60 lakh, up from ₹13,599.60 lakh in the prior year. Profit before tax for the year was ₹3,817.45 lakh, a significant increase from ₹2,436.73 lakh in FY25. Basic earnings per share for the year improved to ₹6.64 from ₹4.42 in the previous year. The following table summarises the full-year and quarterly standalone financial highlights:

The quarterly performance further highlights the company's improving profitability trajectory, with Q4 EBITDA margin expanding significantly on a year-on-year basis:

Corporate Actions

The Board of Directors, in its meeting held on May 30, 2026, approved the re-appointment of M/s Sanjay Kumar Garg & Associates as Cost Auditor for FY27. The appointment is subject to the ratification of remuneration by shareholders at the ensuing Annual General Meeting. The firm's registration number is 100292. Additionally, the board appointed Mr. Pankaj Kumar Gupta as the scrutinizer for the 34th Annual General Meeting to be held in 2026. The subdivision of equity shares from a face value of ₹10 to ₹2 each was effective from February 20, 2026.

Consolidated Results

On a consolidated basis, the company reported a net profit of ₹2,988.52 lakh for FY26, compared to ₹2,153.16 lakh in the previous year. The consolidated results include the financials of associate companies Peptech Biosciences Limited and Titan Media Limited. Total comprehensive income for the year stood at ₹2,979.70 lakh.

Titan Biotech Limited has scheduled a meeting of its Board of Directors on Saturday, May 30, 2026. The meeting will be held at the company's registered office in Delhi to discuss key financial agenda items for the financial year ended March 31, 2026.

The primary focus of the board meeting will be to consider and approve the audited financial results for the fiscal year, both standalone and consolidated. In addition to the financial results, the directors will evaluate and potentially recommend a dividend on equity shares for the financial year ended March 31, 2026, subject to the board's approval.

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, Titan Biotech Limited has closed the trading window for designated persons. The closure is effective from Wednesday, April 1, 2026, and will remain in effect until 48 hours after the declaration of the board meeting's outcome on May 30, 2026.

Meeting Details

The board meeting will take place at 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India. The company has informed the stock exchanges regarding the schedule and the closure of the trading window.